Olmsted County, Minn., funds by Health and Human Services, Department of
Listing $69,277,935.62 in stimulus funds from Health and Human Services, Department of for Olmsted
Note: For some programs where states do not report where money will be distributed across the state, we do not have the allocation for individual counties. Those programs include: Medicaid, unemployment benefits and food stamps. Those amounts are included in the totals for where the state agency receiving that money is located.
Amount refers to both the amount of stimulus funding going toward the project and the face value of the loan.
| Recipient | Amount | Description | Federal Dept./Agency | Date |
|---|---|---|---|---|
| MAYO CLINIC | $7,963,231 |
ARRA - Strategic Health IT Advanced Research Projects (SHARP) We propose research that will generate a framework of open source services that can be dynamically configured to transform HER data into standards-conforming, comparable information suitable for large-scale analyses, inferencing, and integegration of dispar... Show more
This spending item is part of a $15,000,000 allocation.
See details
|
Health and Human Services, Department of | 3/19/2010 |
| MAYO CLINIC | $4,231,735 |
ARRA - Health Information Technology - Beacon Communities The Beacon Community Cooperative Agreement Program will provide funding to communties to build and strengthen their health information technology (health IT) infrastructure and exchange capabilities to demonstrate the vision of the future wherere hospitals,... Show more
This spending item is part of a $12,284,770 allocation.
See details
|
Health and Human Services, Department of | 5/04/2010 |
| CHILD CARE RESOURCE & REFERRAL INC | $3,109,625 | ARRA - Early Head Start This award provides for ARRA Early Head Start Expansion funding to serve 120 pregnant women, infants, and toddlers in Olmsted County and the City of Albert Lea. The Early Head Start (EHS) program provides family-centered services for low-income families | Administration for Children and Families | 11/25/2009 |
| MAYO CLINIC | $2,500,008 | Trans-NIH Recovery Act Research Support The Mayo Clinic Center for the Individual Treatment of Alcohol Dependence (CITA) is a P20 exploratory/ developmental alcohol research center proposal with the over-arching theme of using translational research strategies to create a new research center wi | National Institutes of Health | 9/30/2009 |
| COUNTY OF OLMSTED | $2,220,933 |
ARRA - Prevention and Wellness--Communities Putting Prevention to Work Minnesota Deapartment of Health (MDH) will use Community Putting Prevention to Work (CPPW) funding to plan, implement, and provide expertise on evidence-based policy, systems, and environmental changes that support healthy behavioiors related to obesity, ph... Show more
This spending item is part of a $5,922,486 allocation.
See details
|
Centers for Disease Control and Prevention | 3/18/2010 |
| MAYO CLINIC | $1,911,769 | Trans-NIH Recovery Act Research Support The U.S. Department of Health and Human Services report '2020:A New Vision' highlights that regenerative medicine is the vanguard of the 21st century healthcare. From bone marrow transplants five decades ago to the most recent stem cell-derived organ tran | National Institutes of Health | 3/31/2010 |
| MAYO CLINIC | $1,699,040 |
Trans-NIH Recovery Act Research Support This application is for funding of a study to characterize the human immune response before and after 2010-2011 influenza A/California/H1N1 seasonal vaccination by developing comprehensive immune profiles utilizing systems biology and bioinformatics appro
This spending item is part of a $3,496,853 allocation.
See details
|
National Institutes of Health | 7/12/2010 |
| MAYO CLINIC | $1,596,142 |
Trans-NIH Recovery Act Research Support Our goal is to determine the clinical, cognitive, imaging, genetic, and biochemical biomarker characteristics of the early (pre-dementia) stages of Alzheimer's disease (AD). The project builds on the NIA-funded AD Neuroimaging Initiative (ADNI1) and serve
This spending item is part of a $23,822,294 allocation.
See details
|
National Institutes of Health | 9/24/2009 |
| MAYO CLINIC | $1,479,657 | Trans-NIH Recovery Act Research Support Arterial disease (arteriosclerosis) is accelerated in the presence of hypertension, a major cardiovascular risk factor that affects more than 65 million people in the USA, resulting in health care costs of ~$110 billion annually. Despite significant advan | National Institutes of Health | 7/17/2009 |
| MAYO CLINIC | $1,418,106 |
Recovery Act Comparative Effectiveness Research - AHRQ At any one time, there are approximately 16 million Americans with depression, a condition associated with decreased quality and diminished duration of life, and with very large costs for society and for the families affected. Lifestyle changes a and self-c... Show more
This spending item is part of a $1,496,528 allocation.
See details
|
Agency for Healthcare Research and Quality | 8/30/2010 |
| COUNTY OF OLMSTED | $1,197,943 |
ARRA - Health Information Technology - Beacon Communities The Beacon Community Cooperative Agreement Program will provide funding to communties to build and strengthen their health information technology (health IT) infrastructure and exchange capabilities to demonstrate the vision of the future wherere hospitals,... Show more
This spending item is part of a $12,284,770 allocation.
See details
|
Health and Human Services, Department of | 5/04/2010 |
| OLMSTED MEDICAL CENTER | $1,127,355 |
ARRA - Health Information Technology - Beacon Communities The Beacon Community Cooperative Agreement Program will provide funding to communties to build and strengthen their health information technology (health IT) infrastructure and exchange capabilities to demonstrate the vision of the future wherere hospitals,... Show more
This spending item is part of a $12,284,770 allocation.
See details
|
Health and Human Services, Department of | 5/04/2010 |
| MAYO CLINIC | $1,069,712 |
Trans-NIH Recovery Act Research Support In 2008, over 66,000 people in the US will be diagnosed with Non-Hodgkin lymphoma (NHL), and over 19,000 will die of this cancer. Survival rates have only recently begun to improve, and the current 5-year survival rate is 66%. We have identified a number
This spending item is part of a $1,230,557 allocation.
See details
|
National Institutes of Health | 7/16/2009 |
| MAYO CLINIC | $1,000,000 | Trans-NIH Recovery Act Research Support This application addresses broad Challenge Area, 04-DK-103: Develop Novel Approaches to Understand and Treat Functional Disorders. We plan to determine the role of diet and how genotype contributes to the development of functional GI and motility disorder | National Institutes of Health | 9/29/2009 |
| MAYO CLINIC | $983,862 | Trans-NIH Recovery Act Research Support This application addresses broad Challenge Area (08) Genomics, and specific Challenge Topic 08-CA-101* Augmenting Genome-Wide Association Studies. The development of glioblastoma (GBM) has been hypothesized to be associated with relatively common germline | National Institutes of Health | 9/24/2009 |
| MAYO CLINIC | $945,723 | Trans-NIH Recovery Act Research Support ADPKD is a common cause of end stage renal disease (ESRD) and, hence, is of significant medical importance and economic burden. A number of different potential therapies are now in Phase III trials with the prospects for an effective therapy in the next f | National Institutes of Health | 9/21/2009 |
| MAYO CLINIC | $924,609 | Trans-NIH Recovery Act Research Support This application addresses broad Challenge Area (05) Comparative Effectiveness Research and specific Challenge Topic, 05-EB-101* - Comparative Effectiveness of Advanced Imaging Procedures. Advances in cross-sectional imaging have revolutionized the medica | National Institutes of Health | 9/23/2009 |
| MAYO CLINIC | $906,630 | Trans-NIH Recovery Act Research Support The broad objective of this new application is to advance our understanding of the pathophysiological mechanisms of human Cardiorenal Syndrome (CRS) with a specific emphasis upon the biological interaction between diuretic therapy, the renin-angiotensin-a | National Institutes of Health | 7/16/2009 |
| MAYO CLINIC | $846,745 | Trans-NIH Recovery Act Research Support This application addresses broad Challenge Area (04) Clinical Research, and specific challenge Topic 04-HL-101: Identify Mechanisms Linking Cardiopulmonary Disease Risk and Sleep Disordered Breathing. Atrial fibrillation (AF), the most common sustained ar | National Institutes of Health | 9/25/2009 |
| BOOZ ALLEN HAMILTON INC. | $821,639 |
The Cancer Knowledge Cloud will connect and share information generated through NCI genomic atlas projects, the caHUB tissue acquisition network, the NCI functional Biology Consortium, NCI patient Characterization Center, the NCI pre-clinical Development
This spending item is part of a $103,000,000 allocation.
See details
|
National Institutes of Health | 11/23/2009 |
| MAYO CLINIC | $797,973 | Trans-NIH Recovery Act Research Support The specific aims of the North Central Cancer Treatment Group (NCCTG) are: 1. to improve the duration and quality of life of cancer patients by performing high-quality multidisciplinary cancer treatment trials, 2. to improve the understanding of cancer bi | National Institutes of Health | 7/16/2009 |
| MAYO CLINIC | $776,684 |
Trans-NIH Recovery Act Research Support Cigarette smoking is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States and accounts for 30% of U.S. cancer deaths. Varenicline and bupropion SR (sustained-release) are non nicotine pharma
This spending item is part of a $1,085,473 allocation.
See details
|
National Institutes of Health | 4/28/2009 |
| CHILD CARE RESOURCE & REFERRAL INC | $774,771 | ARRA - Head Start This award provides for ARRA Head Start Expansion funding to serve an additional 40 children and their families. The program provides comprehensive health, developmental and family-centered services for low-income families to promote the school readiness | Administration for Children and Families | 9/14/2009 |
| MAYO CLINIC | $759,405 | Trans-NIH Recovery Act Research Support The Mayo Clinic CTSA is in the process of transforming the Mayo Clinic Biomedical Mass Spectrometry facility into a Metabolomics Core. This will fill a gap in our novel technology facilities at Mayo Clinic and will substantially strengthen translational r | National Institutes of Health | 9/15/2009 |
| MAYO CLINIC | $756,867 |
Trans-NIH Recovery Act Research Support This application addresses Challenge Area #15:Translational Science and Specific Challenge Topic, 15-HD-102: Pelvic Pain. We propose to characterize the pain with menses and noncyclic pelvic pain in women with uterine leiomyomas at baseline and following
This spending item is part of a $974,131 allocation.
See details
|
National Institutes of Health | 9/30/2009 |
| MAYO CLINIC | $752,195 | Trans-NIH Recovery Act Research Support Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. Despite increasing understanding of the pathophysiology of IBS, there are unmet clinical needs and no effective medication approved for the treatment of abdominal pain associated wit | National Institutes of Health | 9/18/2009 |
| MAYO CLINIC | $696,204 | Trans-NIH Recovery Act Research Support Lung disease is the third leading cause of mortality in the United States, has an economic impact of over $154 billion (USD) a year and in its chronic form impacts the lives of over 35 million Americans. Interstitial lung disease (ILD), which includes ove | National Institutes of Health | 8/11/2009 |
| MAYO CLINIC | $683,118 | Trans-NIH Recovery Act Research Support This study is designed to follow through on unique observations made during our last period of funding which established the importance of p16 in treatment response to photodynamic therapy (PDT). We also showed that PDT was able to eliminate most biomarke | National Institutes of Health | 6/05/2009 |
| MAYO CLINIC | $668,560 | Trans-NIH Recovery Act Research Support Barrett's esophagus (BE), a well-known complication of GER, is the strongest known precursor of esophageal adenocarcinoma (EAC). Thus, identifying effective screening approaches for the early detection of BE are highly desired. Current impediments to BE s | National Institutes of Health | 9/30/2010 |
| MAYO CLINIC | $667,981 | Trans-NIH Recovery Act Research Support The overall goal of this proposal is to address the clinical problem of detecting impairment of myocardial microcirculatory function, such as occurs in atherosclerosis, prior to symptoms due to narrowing of epicardial coronary arteries or due to myocardia | National Institutes of Health | 7/16/2009 |
| MAYO CLINIC | $618,547 |
Trans-NIH Recovery Act Research Support Studies are currently underway to examine the genetic factors contributing to a range of addictions, including critical public health problems like smoking and alcohol abuse. New approaches use emerging technologies-such as genome-wide association studies
This spending item is part of a $767,689 allocation.
See details
|
National Institutes of Health | 7/16/2009 |
| MAYO CLINIC | $610,262 |
Trans-NIH Recovery Act Research Support This is a revised, competitive renewal application for the Genetics of Microangiopathic Brain Injury (GMBI) study, initially funded in 2001 as an ancillary study to the Genetic Epidemiology Network of Arteriopathy (GENOA) and Family Blood Pressure Program
This spending item is part of a $1,666,669 allocation.
See details
|
National Institutes of Health | 8/04/2009 |
| MAYO CLINIC | $597,475 | Trans-NIH Recovery Act Research Support Non-Hodgkin lymphoma (NHL) is now the 5th most frequently diagnosed cancer among both men and women in the US. There is rapidly accumulating evidence for several candidate susceptibility genes in the etiology of NHL, supporting a polygenic model based on | National Institutes of Health | 9/18/2009 |
| MAYO CLINIC | $562,984 |
Trans-NIH Recovery Act Research Support This application, 'Epigenetic Biomarkers of Common Chronic Diseases,' addresses broad Challenge Area (03) Biomarker Discovery and Validation and specific Challenge Topic, 03-OD-101: Use of Epigenetic Signatures in Blood Cells to Predict Disease. Diabetes,
This spending item is part of a $998,684 allocation.
See details
|
National Institutes of Health | 9/23/2009 |
| OLMSTED MEDICAL CENTER | $560,000 | Herpes and Zoster Study (part 2) Herpes Trends and Risk Factor Effectiveness. Special Study ? not R&D. Study Designed to obtain data and trend herpes zoster incidence to monitor the impact of the zoster vaccine program. | Centers for Disease Control and Prevention | 9/22/2009 |
| MAYO CLINIC | $538,033 | Trans-NIH Recovery Act Research Support This application is being submitted in response to Notice Number NOT-OD-09-058, NIH Announces the Availability of Recovery Act Funds for Competitive Revision Applications. This competitive revision application pertains to parent grant 1RO1 AG026094, The S | National Institutes of Health | 9/21/2009 |
| MAYO CLINIC | $527,861 |
Trans-NIH Recovery Act Research Support This application addresses the broad Challenge Area (15) Translational Science and the specific Challenge Topic 15-LM-103: In silico hypothesis testing for biology and medicine. The objective of this project is to determine the feasibility of mathematical
This spending item is part of a $931,419 allocation.
See details
|
National Institutes of Health | 8/12/2010 |
| MAYO CLINIC | $498,635 |
Trans-NIH Recovery Act Research Support This application addresses broad Challenge Area (11): Regenerative Medicine and specific Challenge Topic 11-AA-102: Roles of Cellular Organelles and the Cytoskeleton in Alcohol-induced Organ Damage. Alcohol abuse and alcohol-induced liver disease are a ma
This spending item is part of a $998,212 allocation.
See details
|
National Institutes of Health | 9/28/2009 |
| MAYO CLINIC | $495,773 |
Trans-NIH Recovery Act Research Support Over the last decade NIH has reported a decrease in the number of physician-scientists applying for research and training awards. 'Increasing advances in the basic sciences that have progressed to clinical relevance have not been matched by an adequate gr
This spending item is part of a $523,069 allocation.
See details
|
National Institutes of Health | 9/16/2009 |
| MAYO CLINIC | $453,300 | Trans-NIH Recovery Act Research Support Diabetic gastroparesis is a serious and debilitating complication of diabetes. In the parent grant to this application, we have tested the central hypothesis that interstitial cells of Cajal (ICC) and neuronal nitric oxide synthase (nNOS) are lost in diab | National Institutes of Health | 9/25/2009 |
| MAYO CLINIC | $446,663 |
Trans-NIH Recovery Act Research Support Functional dyspepsia is a common, chronic and costly disorder that substantially impairs quality of life for many Americans. The pathogenesis is unclear but abnormalities of gastric motor and sensory function have been identified; it is uncertain if the r
This spending item is part of a $496,120 allocation.
See details
|
National Institutes of Health | 7/02/2010 |
| MAYO CLINIC | $415,525 | Trans-NIH Recovery Act Research Support Corneal endothelial cell dysfunction causes decreased vision and can only be treated by corneal transplantation to replace human corneal endothelial cells (HCECs), which do not proliferate in vivo. Over 15,000 corneal transplants are performed every year | National Institutes of Health | 8/04/2009 |
| MAYO CLINIC | $413,691 |
Trans-NIH Recovery Act Research Support Our primary objective is to identify specific gene variants that are related to the formation and rupture of intracranial aneurysms (IA). Our experienced collaborative and highly productive team of Familial Intracranial Aneurysm (FIA) Investigators at 27
This spending item is part of a $8,081,413 allocation.
See details
|
National Institutes of Health | 9/14/2009 |
| MAYO CLINIC | $411,290 |
Supplemental funding to an exisitng contract is being provided under the CTEP Accelerating Clinical Trials of Novel Oncologic PathWays (ACTNOW) program for a protocol entitled 'Phase II trial of CDK inhibitor SCH727965 in multiple myeloma'. Multiple myel
This spending item is part of a $499,997 allocation.
See details
|
National Institutes of Health | 8/31/2009 |
| MAYO CLINIC | $406,331 | Trans-NIH Recovery Act Research Support The proposed studies address very basic questions about the postnatal growth of phrenic motoneurons and diaphragm muscle (DIAm) fibers. Such growth of phrenic motoneurons and DIAm fibers is necessary to meet the increasing functional diversity of the DIAm | National Institutes of Health | 9/21/2009 |
| MAYO CLINIC | $394,250 | Trans-NIH Recovery Act Research Support Background: Food intolerances are a common complaint, of which gluten sensitivity is one of the most common and serious. It has 2 distinct manifestations, Celiac Disease (CD) and Dermatitis Herpetiformis (DH), which affect 1% of the population, a number t | National Institutes of Health | 7/12/2010 |
| MAYO CLINIC | $393,775 | Trans-NIH Recovery Act Research Support The ultimate goal of virtually all immunological research is to generate medicines that would allow precise therapeutic control of the human immune system. Drugs that would control T cell function are sought with the aim of preventing organ transplant rej | National Institutes of Health | 6/14/2010 |
| MAYO CLINIC | $347,136 | Trans-NIH Recovery Act Research Support The development and conduct of clinical trials consists of a coordinated set of activities beginning with concept development and continuing through protocol development and activation, data quality control, auditing, and results reporting. The time consu | National Institutes of Health | 7/02/2010 |
| MAYO CLINIC | $343,063 | Trans-NIH Recovery Act Research Support The long-term goal of our research is to understand the anatomic and biochemical factors that control aquaeous outflow resistance in the normal eye, and the pathophysiologic changes that occur in glaucomatous eyes. We hypothesized in R01-EY07065 (funding | National Institutes of Health | 9/16/2009 |
| MAYO CLINIC | $325,983 |
Trans-NIH Recovery Act Research Support Chronic lymphocytic leukemia (CLL) is a malignant B cell lymphoproliferative disorder and is most common in Caucasians, with a lifetime risk of 1 in 200. It has been known for decades that a genetic component affects CLL risk, with the risk of CLL on the
This spending item is part of a $616,035 allocation.
See details
|
National Institutes of Health | 8/31/2009 |
| MAYO CLINIC | $315,427 |
Trans-NIH Recovery Act Research Support Palliative care, a relatively new subspecialty, needs to build its evidence base supporting clinical practice. The Institute of Medicine has identified palliative care as a comparative effectiveness research priority, but increased scientific productivity
This spending item is part of a $7,175,320 allocation.
See details
|
National Institutes of Health | 9/30/2010 |
| MAYO CLINIC | $310,590 |
Trans-NIH Recovery Act Research Support ARRA: BIOMARKER PREDICTION OF GLEASON UPGRADING Over treatment of prostate cancer (treatment that does not extend lifespan) has increased dramatically with the advent of PSA testing. Active surveillance (AS) is an approach to reduce over treatment by care
This spending item is part of a $1,956,421 allocation.
See details
|
National Institutes of Health | 9/29/2009 |
| MAYO CLINIC | $302,191 | Trans-NIH Recovery Act Research Support Women who carry inactivating mutations in the BRCA1 and BRCA2 genes in their germline are at significantly elevate risk of breast and ovarian cancer. Because of the identification of these mutations by clinical genetic testing many mutation carriers are a | National Institutes of Health | 9/15/2009 |
| MAYO CLINIC | $301,942 | Trans-NIH Recovery Act Research Support Breast cancer is the most frequent malignancy in women, and is associated with significant morbidity and mortality. Few commonly inherited genetic alterations that contribute to the etiology of this disease have been defined. The goal of our ongoing study | National Institutes of Health | 9/17/2009 |
| MAYO CLINIC | $299,998 | Trans-NIH Recovery Act Research Support The CTSA Consortium Strategic Goal #1 seeks to improve clinical and translational research management capability. The administrative and regulatory infrastructure supporting clinical research is often a key determinant of the success of funding applicatio | National Institutes of Health | 9/14/2009 |
| MAYO CLINIC | $299,176 | Trans-NIH Recovery Act Research Support Recently, there has been an increased interest in 'individualized medicine' and thus pharmacogenetics and pharmacogenomics in cancer research have moved to the forefront as well. Pharmacogenetics is the study of the role of inheritance in individual varia | National Institutes of Health | 5/21/2009 |
| MAYO CLINIC | $283,085 |
Trans-NIH Recovery Act Research Support The vast majority of HIV-1 infections occur at mucosal surfaces in the body. There is therefore an immediate need for potent HIV vaccines that can provide barrier protection at mucosal surfaces. While there is this need,most HIV vaccines have been develop
This spending item is part of a $720,202 allocation.
See details
|
National Institutes of Health | 9/11/2009 |
| MAYO CLINIC | $269,585 |
Trans-NIH Recovery Act Research Support The RELIVE (Renal and Lung Living Donors Evaluation) Study is a National Institute of Allergy and Infectious Diseases (NIAID) funded, multi-site effort to determine the long-term risks of live donor nephrectomy 5-50 years later for donors at Mayo Clinic a
This spending item is part of a $861,615 allocation.
See details
|
National Institutes of Health | 6/28/2010 |
| MAYO CLINIC | $265,742 |
Trans-NIH Recovery Act Research Support This application addresses the broad Challenge Area (05) Comparative Effectiveness Research and the specific Challenge Topic: 05-NS-104* Intervention vs. Best Medical Therapy in Asymptomatic Persons With Identified Vascular Abnormalities. The Internationa
This spending item is part of a $967,907 allocation.
See details
|
National Institutes of Health | 9/25/2009 |
| MAYO CLINIC | $265,565 |
The Contractor shall provide services to the National Institute of Biomedical Imaging and Bioengineering (NIBIB) in the design, development, and launch of an Internet-based network for patient-controlled medical image sharing built upon the Integrating th
This spending item is part of a $4,697,377 allocation.
See details
|
National Institutes of Health | 9/30/2009 |
| MAYO CLINIC | $264,824 |
Trans-NIH Recovery Act Research Support The overall goal of this competitive revision is a rigorous evaluation of the potential of engineered cocaine hydrolases alone and in combination with antibodies to ameliorate cocaine toxicity and cocaine abuse by preventing cocaine access to targets. Our
This spending item is part of a $732,603 allocation.
See details
|
National Institutes of Health | 9/21/2009 |
| MAYO CLINIC | $255,711 | Trans-NIH Recovery Act Research Support This Recovery Act Administrative Supplement request to R01 HL090595 is to provide employment for a postdoctoral fellow to accelerate the pace of progress on the PI's parent grant by working on a subset of projects already outlined in the grant. In this co | National Institutes of Health | 7/16/2009 |
| COUNTY OF OLMSTED | $253,813 |
ARRA - Community Services Block Grant ARRA supplemental funding for the Community Services Block Grant (CSBG) program provided funds to a network of eligible organizations to support employment related services that created and sustained economic growth with a particular focus on people livin
This spending item is part of a $12,032,251 allocation.
See details
|
Administration for Children and Families | 4/10/2009 |
| MAYO CLINIC | $247,477 |
Trans-NIH Recovery Act Research Support Our proposal addresses the following challenge area: 06-LM-101* Intelligent Search Tool for Answering Clinical Questions. Develop new computational approaches to information retrieval that would allow a clinician or clinical researcher to pose a single qu
This spending item is part of a $497,477 allocation.
See details
|
National Institutes of Health | 9/24/2009 |
| MAYO CLINIC | $245,908 |
Trans-NIH Recovery Act Research Support The goal of this proposal is to examine how impairments and alterations in trafficking and targeting of lipid droplets (LD) to specific organelles influences LD accumulation in steatosis and contributes to alcohol-induced fatty liver disease (AFLD). We h
This spending item is part of a $499,999 allocation.
See details
|
National Institutes of Health | 9/28/2009 |
| MAYO CLINIC | $245,309 |
Enhancing ITK for Research, Education, and Clinical Interoperability.
This spending item is part of a $862,699 allocation.
See details
|
National Institutes of Health | 6/21/2010 |
| MAYO CLINIC | $245,100 |
Trans-NIH Recovery Act Research Support The American College of Surgeons Oncology Group (ACOSOG) is dedicated to improving the care of the surgical oncology patient through an innovative clinical research program addressing three specific aims: 1. To test novel therapies that may increase respo
This spending item is part of a $259,351 allocation.
See details
|
National Institutes of Health | 6/18/2010 |
| MAYO CLINIC | $241,867 | Trans-NIH Recovery Act Research Support This Recovery Act Administrative Supplement request to R01 HL-81753 is designed to support a postdoctoral fellow, Dr. Yonghe Ding, and accelerate the collection of data associated with the parent award. Dr. Ding will replace Mr. Ruilin Zhang, a graduate s | National Institutes of Health | 7/16/2009 |
| MAYO CLINIC | $237,227 | Trans-NIH Recovery Act Research Support This is an administrative supplement request for parent grant Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging, R01 AG11378. The performance dates of the parent grant are 9/1/2008-7/31/2013. The overall goal of this parent | National Institutes of Health | 9/14/2009 |
| MAYO CLINIC | $228,200 | Trans-NIH Recovery Act Research Support The decline of contractility with ischemia - reperfusion is multifactorial. The parent grant, HL78845, aimed to define the root causes of the contractility decline by focusing on three specific aims: 1) To test the hypothesis that ischemia - reperfusion r | National Institutes of Health | 7/16/2009 |
| MAYO CLINIC | $225,000 | Trans-NIH Recovery Act Research Support The North Central Cancer Treatment Group (NCCTG) has need of Information Technology (IT) resources to support the development and integration of standardized IT tools to reduce the administrative burden on study investigators. The NCCTG IT staff is curren | National Institutes of Health | 9/21/2009 |
| MAYO CLINIC | $223,557 |
Trans-NIH Recovery Act Research Support Type 2 diabetes mellitus (DM2), is causally associated with coronary artery disease (CAD), and is a major health and economic burden. Despite multiple preventive and therapeutic measures implemented in the last few decades to decrease the occurrence and p
This spending item is part of a $1,160,811 allocation.
See details
|
National Institutes of Health | 8/14/2009 |
| MAYO CLINIC | $222,948 | The Mayo Foundation has been awarded a contract to provide tumor types to the NCI for The Cancer Genome Atlas (TCGA) project. Specifically this award is to fund the provision of hepatocellular cases. These cases are all primary and untreated. The colle | National Institutes of Health | 6/25/2010 |
| MAYO CLINIC | $221,010 |
Trans-NIH Recovery Act Research Support The systemic vasculitides are a group of diseases characterized by severe inflammation of blood vessels leading to arterial stenosis or occlusion, and organ damage or death if untreated. Two related vasculitides, Wegener's granulomatosis (WG) and microsco
This spending item is part of a $1,000,000 allocation.
See details
|
National Institutes of Health | 9/29/2009 |
| MAYO CLINIC | $220,557 |
Trans-NIH Recovery Act Research Support This is an ARRA Administrative Supplement proposal for U01DK062410 Polycystic Kidney Disease-Treatment Network (HALT PKD): Controlled Trials of Renin Angiotensin Blockade in Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Mayo Clinic (with subco
This spending item is part of a $423,547 allocation.
See details
|
National Institutes of Health | 9/21/2009 |
| MAYO CLINIC | $210,358 |
Recovery Act Comparative Effectiveness Research - AHRQ 'In response to RFA-10-003: AHRQ Clinical and Health Outcomes Initiative in Comparative Effectiveness: the goal of this project is to conduct a randomized controlled multi-center clinical trial to determine whether using the Online Wound Electrononic Medica... Show more
This spending item is part of a $9,645,674 allocation.
See details
|
Agency for Healthcare Research and Quality | 9/28/2010 |
| MAYO CLINIC | $208,207 |
Trans-NIH Recovery Act Research Support We plan a multi-center study to accurately describe the natural history of late kidney transplant failure, and to dissect out individual entities leading to late deterioration of function and to graft loss. Previous studies, and the current literature, at
This spending item is part of a $1,128,568 allocation.
See details
|
National Institutes of Health | 6/28/2010 |
| MAYO CLINIC | $206,567 |
Trans-NIH Recovery Act Research Support Prostate cancer is a leading cause of cancer related morbidity and mortality in US males. Despite initial treatments with curative intent for localized stage (surgery or radiation) approximately one third patients will progress to advanced stages. This h
This spending item is part of a $391,855 allocation.
See details
|
National Institutes of Health | 7/16/2009 |
| MAYO CLINIC | $205,254 |
Trans-NIH Recovery Act Research Support This is a proposal to validate the accuracy of a multi-gene Lung Cancer Risk Test (LCRT). An accurate LCRT may be used to design more efficient lung cancer screening and/or chemoprevention studies by enabling enrollment of the highest risk individuals, re
This spending item is part of a $799,426 allocation.
See details
|
National Institutes of Health | 9/30/2009 |
| MAYO CLINIC | $205,254 |
Trans-NIH Recovery Act Research Support This is a proposal to validate the accuracy of a multi-gene Lung Cancer Risk Test (LCRT). An accurate LCRT may be used to design more efficient lung cancer screening and/or chemoprevention studies by enabling enrollment of the highest risk individuals, re
This spending item is part of a $1,649,791 allocation.
See details
|
National Institutes of Health | 9/30/2009 |
| CHILD CARE RESOURCE & REFERRAL INC | $205,000 | ARRA - Head Start This award provides for Head Start Training and Technical Assistance to improve the qualifications and training of teaching staff in Head Start and Early Head Start programs through the use of Early Learning Mentor Coaches. Head Start and Early Head Star | Administration for Children and Families | 9/15/2010 |
| MAYO CLINIC | $199,336 |
Trans-NIH Recovery Act Research Support Title: CNV Atlas of Human Development Abstract: The recent discovery that copy number variations (CNVs), the loss or gain of small genomic segments, is common in all normal individuals and plays a major role in human phenotypic variation and disease, has
This spending item is part of a $3,423,980 allocation.
See details
|
National Institutes of Health | 9/29/2009 |
| CHILD CARE RESOURCE & REFERRAL INC | $197,662 |
ARRA Child Care and Development Block Grant Title: ARRA Supplemental Funding for the Child Care Development Fund (CCDF). Description: Provide child care financial assistance to low-income working families and fund activities to improve the quality of child care.
This spending item is part of a $26,097,341 allocation.
See details
|
Administration for Children and Families | 4/09/2009 |
| MAYO CLINIC | $192,059 |
Trans-NIH Recovery Act Research Support The Colon Cancer Family Registry (C-CFR) is an international consortium that provides a comprehensive collaborative infrastructure for studies of the genetics and epidemiology of colorectal cancer (CRC). The CCFR was founded by NCI in 1997 as a UO1 under
This spending item is part of a $222,055 allocation.
See details
|
National Institutes of Health | 9/15/2009 |
| MAYO CLINIC | $192,019 |
Trans-NIH Recovery Act Research Support Increased mammographic breast density is one of the strongest risk factors for breast cancer, is common in the population, and may account for a large proportion of cases of breast cancer. This supplement enhances the overall goal of R01 CA128931 to ident
This spending item is part of a $269,744 allocation.
See details
|
National Institutes of Health | 9/21/2009 |
| MAYO CLINIC | $188,617 | Trans-NIH Recovery Act Research Support Rheumatoid arthritis (RA) and its animal model collagen-induced arthritis (CIA) are known to be T and B cell dependent diseases. HLA-DQ8 and DRB1*0401 molecules render humans and mice susceptible to develop arthritis while DQ6 and DRB1*0402 provide protec | National Institutes of Health | 6/28/2010 |
| MAYO CLINIC | $187,364 |
Trans-NIH Recovery Act Research Support A wide array of inherited human diseases are caused by mutations in our mitochondrial DNA (mtDNA) genome and in mitochondrial genes encoded in the nuclear genome, but there are currently no effective therapies for these clinically devastating diseases. We
This spending item is part of a $410,249 allocation.
See details
|
National Institutes of Health | 5/15/2009 |
| MAYO CLINIC | $183,960 |
The Standards Development team will act as a convener and coordinator in engaging the Standards Development Organizations (SDOs) to identify, analyze and, as necessary, modify the existing standards to support the core functional requirements defined by t
This spending item is part of a $6,890,581 allocation.
See details
|
Program Support Center | 3/18/2011 |
| MAYO CLINIC | $182,831 | Trans-NIH Recovery Act Research Support The goal of the parent proposal Mechanisms of aggregation in light chain Amyloidosis is to dissect the molecular mechanisms that cause light chain amyloidosis (AL) deposits to form. AL is a devastating disease caused by the abnormal proliferation of plasm | National Institutes of Health | 8/10/2009 |
| MAYO CLINIC | $180,389 | Trans-NIH Recovery Act Research Support One of the two central hypotheses of the parent grant (R01 AR27065) was that bone strength estimates by finite element (FE) analyses, which can now be obtained from clinical quantitative computed tomography (QCT) images, will enhance the ability to identi | National Institutes of Health | 9/18/2009 |
| MAYO CLINIC | $173,006 |
Trans-NIH Recovery Act Research Support There are more persons who die from lung cancer than from breast, colon, and prostate cancer combined. The objective of the Genetic Epidemiology of Lung Cancer Consortium (GELCC) is to conduct family-based studies to identify susceptibility genes in famil
This spending item is part of a $880,446 allocation.
See details
|
National Institutes of Health | 9/17/2009 |
| MAYO CLINIC | $165,000 |
We have been awarded a contract to provide tumor types to the NCI for The Cancer Genome Atlas (TCGA) project. Specifically to establish a Tissue Source Site (TSS) Network capable of delivering clinically annotated biospecimens through either or both retr
This spending item is part of a $2,725,275 allocation.
See details
|
National Institutes of Health | 9/27/2010 |
| MAYO CLINIC | $161,254 | Trans-NIH Recovery Act Research Support Drug-induced liver injury (Dill) remains a major public health problem of national and worldwide importance. In turn, the National Institutes of Health created the Drug Induced Liver Injury Network (DILlN) in 2003 to stimulate and facilitate research on t | National Institutes of Health | 9/30/2010 |
| MAYO CLINIC | $157,070 | Trans-NIH Recovery Act Research Support Sphingolipids (SLs) play roles in a wide variety of cell functions, including cell-cell interactions, cell growth and differentiation, and signal transduction. SLs can interact with cholesterol to form membrane microdomains, and data from many studies sug | National Institutes of Health | 9/30/2009 |
| MAYO CLINIC | $151,992 | Trans-NIH Recovery Act Research Support The overall goal of our program remains the same: to increase the number of individuals from underrepresented groups who choose biomedical research careers, especially disease-oriented research. Our hypothesis is that more students from underrepresented g | National Institutes of Health | 7/20/2009 |
| MAYO CLINIC | $151,100 | Trans-NIH Recovery Act Research Support Novel therapeutic targets for the treatment of chronic obstructive pulmonary disease (COPD) are urgently needed, as the incidence of COPD - a chronic inflammatory lung disease that imposes tremendous economic burden on the health care system - is increasi | National Institutes of Health | 5/08/2009 |
| MAYO CLINIC | $150,801 | Trans-NIH Recovery Act Research Support Autosomal recessive polycystic kidney disease (ARPKD) is an important genetic disorder in pediatric practice. ARPKD is a renal and hepatic disease in neonates and infants, and <30% of affected neonates die because of greatly enlarged kidneys detected in | National Institutes of Health | 8/14/2009 |
| CHILD CARE RESOURCE & REFERRAL INC | $148,310 | ARRA - Head Start This award provides for an ARRA Cost of Living Adjustment (COLA) and Quality Improvement Funding consistent with the provisions of Section 640(a)(5) of the Head Start Act for the Head Start program. Head Start promotes the school readiness of low-income c | Administration for Children and Families | 6/02/2009 |
| MAYO CLINIC | $148,168 | Trans-NIH Recovery Act Research Support Obesity is an important public health problem. Endoscopic intra-gastric injection of botulinum toxin A (BTA) has been reported to cause weight loss, however results of published studies vary. Our long-term objective is to determine whether alterations in | National Institutes of Health | 7/27/2010 |
| MAYO CLINIC | $145,913 | Trans-NIH Recovery Act Research Support This proposal seeks ARRA supplemental administrative funding for the hiring of a recent college graduate. The parent grant (HL-89331) is currently in year two out of five, and was awarded to Dr. Eisenach as a New Investigator. The scientific activities pr | National Institutes of Health | 7/16/2009 |
| MAYO CLINIC | $133,420 | Trans-NIH Recovery Act Research Support The purpose of this administrative supplement is to accelerate progress of the parent R01 by defining the secretory phenotype of senescent preadipocytes using expression profiling approaches. This is based on new data since the parent grant was submitted | National Institutes of Health | 9/04/2009 |
| MAYO CLINIC | $128,887 |
Trans-NIH Recovery Act Research Support This competitive revision grant proposes to identify novel peptide inhibitors for the digestive enzyme chymotrypsin C. The parent grant investigates how chymotrypsin C regulates activation and degradation of other digestive enzymes and how mutations in ch
This spending item is part of a $566,265 allocation.
See details
|
National Institutes of Health | 9/29/2009 |
| MAYO CLINIC | $123,752 |
Trans-NIH Recovery Act Research Support Osteoarthritis (OA) affects 27 million Americans, many of whom have concomitant symptomatic meniscal tear. Arthroscopic partial meniscectomy (APM) is the surgical procedure used to treat these patients when conservative measures are not successful. The ef
This spending item is part of a $1,372,153 allocation.
See details
|
National Institutes of Health | 9/28/2009 |
| Mayo Clinic | $118,104 |
Trans-NIH Recovery Act Research Support The Epilepsy Phenome/Genome Project is investigating how genes influence the phenotypes of common and rare epilepsies and has proposed to accelerate collection of phenotypic information by hiring a research assistant at each clinical center.
This spending item is part of a $1,558,189 allocation.
See details
|
National Institutes of Health | 9/25/2009 |
| MAYO CLINIC | $114,836 | Trans-NIH Recovery Act Research Support The long term objective of our work is to better understand the pathogenesis of Graves' ophthalmopathy (GO) in order to aid in the the development of new approaches to treatment or prevenetion of this disease. The goal of the laboratory investigations in | National Institutes of Health | 4/29/2010 |
| MAYO CLINIC | $111,454 |
Trans-NIH Recovery Act Research Support Comparative Effectivenss Research in Pediatric Rheumatic Diseases: Leveraging CA -- The study of childhood rheumatic conditions has been challenged by disease heterogeneity, poor understanding of underlying pathophysiology, small sample sizes, and limit
This spending item is part of a $994,839 allocation.
See details
|
National Institutes of Health | 9/28/2009 |
| MAYO CLINIC | $109,214 |
NCI's Community Cancer Centers Program (NCCCP) - The network of community hospitals is a complex pilot program whose mission is, through research, to determine ways to bring state of the art cancer care and clinical trials to patients in their local comm
This spending item is part of a $75,135,000 allocation.
See details
|
National Institutes of Health | 9/04/2009 |
| Southeastern Minnesota Area Agency On Aging Inc | $108,976 |
Aging Congregate Nutrition Services for States ARRA provided funding for Congregate Nutrition Services. Established in 1972 under the Older Americans Act, the program provides meals to older Americans in congregate facilities such as senior centers, adult day centers, and faith-based settings.
This spending item is part of a $1,041,940 allocation.
See details
|
Administration on Aging | 3/18/2009 |
| MAYO CLINIC | $104,699 |
Trans-NIH Recovery Act Research Support We propose to apply high throughput genomic technologies to examine the relationship between the vaginal microbial community (microbiome) and two significant problems impacting women?s health, bacterial vaginosis (BV) and preterm birth, the most significa
This spending item is part of a $659,510 allocation.
See details
|
National Institutes of Health | 9/07/2010 |
| MAYO CLINIC | $104,276 |
Trans-NIH Recovery Act Research Support This administrative supplement is to fund a fulltime post doctoral fellow to support the completion of the in vitro experiments and to train more investigators in the field of valvular heart disease.
This spending item is part of a $251,573 allocation.
See details
|
National Institutes of Health | 7/15/2009 |
| MAYO CLINIC | $104,205 |
Recovery Act Comparative Effectiveness Research - AHRQ Low back pain is one of the most important causes of functional limitation and disability, an Institute of Medicine priority condition, and it remains a particularly important problem for the elderly, an AHRQ priority population. While there are e numerous ... Show more
This spending item is part of a $9,887,064 allocation.
See details
|
Agency for Healthcare Research and Quality | 9/28/2010 |
| GANNON CONSULTING, LLC | $104,135 |
ARRA Child Care and Development Block Grant Title: ARRA Supplemental Funding for the Child Care and Development Fund (CCDF); Description: The CCDF ARRA funds will be used to provide child care financial assistance to low-income working families and fund activities to improve the quality of child ca
This spending item is part of a $4,036,095 allocation.
See details
|
Administration for Children and Families | 4/09/2009 |
| MAYO CLINIC | $103,435 |
Trans-NIH Recovery Act Research Support A robust Pilot and Feasibility Program will be an integral portion of the Mayo Clinic Urology O'Brien Center. The Center currently funds 2 projects at all times. The primary focus is to support new investigators interested nephrolithiasis (NL) research. T
This spending item is part of a $181,320 allocation.
See details
|
National Institutes of Health | 12/07/2009 |
| MAYO CLINIC | $100,783 | Trans-NIH Recovery Act Research Support The underlying genetic factors that influence determinants of urinary SS, such as calcium excretion, are poorly defined. This project addresses these gaps in knowledge by identifying genetic associations with urinary lithogenic factors. To do so we have a | National Institutes of Health | 9/24/2009 |
| MAYO CLINIC | $99,999 | Trans-NIH Recovery Act Research Support The requested funds will be used to secure employment for a post-doctoral research scientist and provide resources to accelerate our research mission of developing a cellbased liver support device for treatment of acute liver failure. Liver failure is a s | National Institutes of Health | 1/31/2010 |
| MAYO CLINIC | $99,998 | Trans-NIH Recovery Act Research Support The Building Partnerships to Promote Health in Low Literacy Populations project has already successfully united the medical/research community with the Hawthorne community to increase understanding of community-based participatory research (CBPR) and to r | National Institutes of Health | 9/25/2009 |
| MAYO CLINIC | $99,602 | Trans-NIH Recovery Act Research Support This administrative supplement application is under the parent grant entitled Alpha-1 Antitrypsin Deficiency and Lung Cancer Risk, R01 CA 80127, ending in May 2011 after a no-cost one-year extension. The proposed project is built on an established rich re | National Institutes of Health | 9/17/2009 |
| MAYO CLINIC | $99,554 | Trans-NIH Recovery Act Research Support Heme oxygenase (HO) metabolizes heme to biliverdin during which iron is released and carbon monoxide (CO) emitted. In 1992, the PI's laboratory provided the first evidence for the cytoprotective effects of HO-1, findings that served as the basis for the f | National Institutes of Health | 9/22/2009 |
| MAYO CLINIC | $99,348 | Trans-NIH Recovery Act Research Support Portal hypertension and its complications account for much of the morbidity and mortality associated with cirrhosis. The Long-Term Goal of our lab is to understand the molecular control mechanisms of portal hypertension. Sinusoidal vasoconstriction is an | National Institutes of Health | 8/06/2009 |
| MAYO CLINIC | $99,323 | Trans-NIH Recovery Act Research Support We are requesting one year's support to retain a post-doctoral research fellow under the American Recovery and Reinvestment Act (ARRA) Administrative Supplement to parent grant R01-EB002834. This capable young scientist has served one year in the Principa | National Institutes of Health | 8/10/2009 |
| MAYO CLINIC | $98,782 | Trans-NIH Recovery Act Research Support This recovery act administrative supplement request to R01 DK57892 is designed to provide a stimulus to the US economy by retaining staff as well as potential long-term opportunities for improving well-being of celiac patients thereby reducing cost to the | National Institutes of Health | 1/12/2010 |
| MAYO CLINIC | $92,353 |
Trans-NIH Recovery Act Research Support Few studies have examined the relationship with gene on the DNA repair and apoptosis pathways. Our preliminary data support associations with several single nucleotide polymorphism in genes in these pathways but a larger sample size is needed to confirm t
This spending item is part of a $1,563,767 allocation.
See details
|
National Institutes of Health | 8/04/2009 |
| MAYO CLINIC | $83,726 |
Trans-NIH Recovery Act Research Support One of the responsibilities of the Eastern Cooperative Oncology Group (ECOG) Operations Office is to coordinate correlative study development, which is done by working closely with ECOG Core Laboratories. ECOGG??s Leukemia Translational Research Laborato
This spending item is part of a $267,561 allocation.
See details
|
National Institutes of Health | 8/31/2009 |
| MAYO CLINIC | $81,250 | The Mayo Foundation has been awarded a contract to provide tumor types to the NCI for The Cancer Genome Atlas (TCGA) project. Specifically this award is to fund the provision of hepatocellular cases. These cases are all primary and untreated. The colle | National Institutes of Health | 8/27/2010 |
| MAYO CLINIC | $80,000 | Trans-NIH Recovery Act Research Support This grant provided a summer research experience for 19 science teachers in health-related scientific research. | National Institutes of Health | 6/01/2009 |
| MAYO CLINIC | $78,163 | Trans-NIH Recovery Act Research Support This Recovery Act Administrative Supplement NOT-OD-09-056 to R01 DK29953 is designed to support a postdoctoral trainee and accelerate the collection of data associated with the parent award. Additionally, it provides an employment opportunity for a talent | National Institutes of Health | 4/19/2010 |
| MAYO CLINIC | $77,459 |
Trans-NIH Recovery Act Research Support Chronic lung diseases represent a broad spectrum of chronic fibrosing/inflammatory lung conditions that are for the most part poorly responsive to treatment and often fatal. COPD/emphysema is the fourth leading cause of death in the United States and the
This spending item is part of a $9,746,871 allocation.
See details
|
National Institutes of Health | 9/25/2009 |
| MAYO CLINIC | $72,589 |
Trans-NIH Recovery Act Research Support The central focus of this proposal explores how to fill a technological gap - the detection of specific A oligomers in living subjects. The development of new techniques for measuring specific A oligomers in living individuals will enable us to investigat
This spending item is part of a $738,783 allocation.
See details
|
National Institutes of Health | 9/24/2009 |
| MAYO CLINIC | $71,395 | Trans-NIH Recovery Act Research Support This supplement request pertains to the activities approved under Aim 1 of RO1 AR48147. The central hypothesis of the parent grant is that Hdac3 and Hdac7 are essential components of a multi-protein complex that regulates Runx2 activity. The objective of | National Institutes of Health | 9/18/2009 |
| MAYO CLINIC | $71,291 |
Trans-NIH Recovery Act Research Support The American College of Surgeons Oncology Group (ACOSOG) is dedicated to improving the care of the surgical oncology patient through an innovative clinical research program addressing three specific aims: 1. To test novel therapies that may increase respo
This spending item is part of a $106,834 allocation.
See details
|
National Institutes of Health | 9/21/2009 |
| Southeastern Minnesota Area Agency On Aging Inc | $70,000 |
ARRA - Communities Putting Prevention to Work: Chronic Disease Self-Manage In collaboration with the Recovery Act-funded Communities Putting Prevention to Work (CPPW) program, this funding will support the deployment of evidence-based chronic disease self-management programs that empower older peoplele with chronic disease to main... Show more
This spending item is part of a $600,000 allocation.
See details
|
Administration on Aging | 3/31/2010 |
| MAYO CLINIC | $69,332 | Trans-NIH Recovery Act Research Support The central importance of the ERBB/RAS signal transduction cascade has been well established in human cancer. Activated ERBB/K-RAS signaling is often associated with the most lethal forms of cancer. The patient genome sequencing projects have recently rev | National Institutes of Health | 9/18/2009 |
| MAYO CLINIC | $65,393 |
Trans-NIH Recovery Act Research Support The mission ofthe Minnesota Obesity Center is to find ways to prevent weight gain, and the onset of obesity and complications of obesity. Obesity is a major source of illness and death, and is the most common nutritional ailment in the United States. Litt
This spending item is part of a $299,999 allocation.
See details
|
National Institutes of Health | 7/20/2009 |
| MAYO CLINIC | $64,209 | Trans-NIH Recovery Act Research Support Recent studies highlight the importance of early precursor lesions in the pathogenesis of NL, a common disease affecting up to 10% of the population. Randall's plaques, first described in the 1930s, are medullary interstitial deposits of calcium phosphate | National Institutes of Health | 11/24/2009 |
| MAYO CLINIC | $53,950 | Trans-NIH Recovery Act Research Support This ARRA Supplement to K08DK76845 Growth Regulatory Mechanisms of KLF in Barrett's Epithelium is a request to expand the personnel support for the aim 3 of K08 to determine the in vivo relevance of KLF11 on the neoplastic transformation in Barrett's muco | National Institutes of Health | 7/20/2009 |
| MAYO CLINIC | $53,783 | Trans-NIH Recovery Act Research Support The administrative supplement will allow an increase in the recruitment of a general population cohort from 400 participants to 600 participant over the next 2 years. This will translate into a relevant improvement in statistical power for comparing renal | National Institutes of Health | 9/30/2009 |
| Southeastern Minnesota Area Agency On Aging Inc | $53,649 |
Aging Home-Delivered Nutrition Services for States ARRA provided funding for Home-Delivered Services. Established in 1978 under the Older Americans Act, the program provides meals to seniors who are homebound.
This spending item is part of a $512,955 allocation.
See details
|
Administration on Aging | 3/18/2009 |
| INDEPENDENT SCHOOL DISTRICT 535 | $47,500 |
ARRA - Head Start The Minnesota Department of Education (MDE) , working with the Governor's Early Learning Council (State Early Childhood Care and Education Council) uses the federal ARRA funds to improve coordination and colalboration among early childhood education and c
This spending item is part of a $1,210,567 allocation.
See details
|
Administration for Children and Families | 5/20/2010 |
| MAYO CLINIC | $32,997 | Trans-NIH Recovery Act Research Support A key objective of the current funding of the ROl grant is to advance our understanding of the regulation of muscle mitochondrial biogenesis and its role in type 2 diabetes. The proposal also addresses the gap in our understanding on regulation of synthes | National Institutes of Health | 2/02/2010 |
| MAYO CLINIC | $31,791 | Trans-NIH Recovery Act Research Support This grant provided a summer research experience for two summer students in health-related scientific research. | National Institutes of Health | 6/16/2009 |
| MAYO CLINIC | $28,289 |
Trans-NIH Recovery Act Research Support This proposal addresses Challenge area 7: Enhancing Clinical Trials: 07-OD(ORDR)-102 for the development of a rare disease genetic patient registry. Peripartum cardiomyopathy (PPCM) is a complication of pregnancy occurring in 1:1800 to 1:3500 births in th
This spending item is part of a $999,818 allocation.
See details
|
National Institutes of Health | 9/21/2009 |
| MAYO CLINIC | $26,133 | Trans-NIH Recovery Act Research Support This grant provided a summer research experience for one summer student in health-related scientific research. | National Institutes of Health | 6/16/2009 |
| MAYO CLINIC | $19,476 |
Trans-NIH Recovery Act Research Support Meniscal tears are frequent sources of disability, especially in persons with concomitant knee osteoarthritis (OA). Observational studies suggest that while arthroscopic partial meniscectomy (APM) consistently relieves symptoms and improves functional sta
This spending item is part of a $170,000 allocation.
See details
|
National Institutes of Health | 9/23/2009 |
| MAYO CLINIC | $14,764 |
Trans-NIH Recovery Act Research Support Primary sclerosing cholangitis (PSC) is one of the most common cholestatic liver diseases among adults in the USA. This disease affects young and middle-aged men and women and may progress to end-stage liver disease requiring liver transplantation. In add
This spending item is part of a $334,663 allocation.
See details
|
National Institutes of Health | 7/23/2010 |
| COUNTY OF OLMSTED | $11,287 |
ARRA - Immunization The costs to fully vaccinate a child, adolescent, or adult have grown substantially in the past ten years because the number of recommended vaccines has increased and new recommendations have expanded the size of vaccination target populations. Current v
This spending item is part of a $1,914,232 allocation.
See details
|
Centers for Disease Control and Prevention | 9/15/2009 |
| MAYO CLINIC | $10,000 |
Trans-NIH Recovery Act Research Support This proposal, entitled ICD Therapy in Patients with Congestive Heart Failure, examines the current use of primary prevention implantable cardioverter defibrillator (ICD) in clinical practice. Although randomized clinical trials have established the ICD a
This spending item is part of a $793,292 allocation.
See details
|
National Institutes of Health | 7/16/2009 |
| MAYO CLINIC | $6,688 | Mayo Foundation has been awarded a contract to provide tumor types to the NCI for the Cancer Genome Atlas (TCGA) project. Specifically this award is to fund the provision of clear cell renal carcinoma tissues (193 cases). These cases are all primary and u | National Institutes of Health | 6/21/2010 |
| MAYO CLINIC ROCHESTER | $5,587 | Trans-NIH Recovery Act Research Support This grant provided a research experience for 1 summer students in health-related scientific research. | National Institutes of Health | 6/01/2009 |
| MAYO CLINIC | $0 |
Trans-NIH Recovery Act Research Support The primary goal of our UOl application titled Optimization of Small-Molecule Inhibitors of Shiga and Ricin Toxins (5UOlAI082120) is to develop second-generation small-molecule inhibitors of Shiga-like toxin 2 (Sro) and ricin. Despite the challenge that s
This spending item is part of a $99,835 allocation.
See details
|
National Institutes of Health | 7/12/2010 |